lapaʻau maʻemaʻe cell renal cell carcinoma

Lapaʻau ʻana i ka maʻi maʻi maʻi maʻi maʻi maʻi maʻemaʻe: He alakaʻi piha ʻO ka hoʻomaopopo ʻana i nā koho no ka mālama ʻana i ka maʻi maʻi maʻi a me ko lākou ʻohana. Hāʻawi kēia alakaʻi i kahi hiʻohiʻona kikoʻī o nā ala lapaʻau o kēia manawa, e kālele ana i nā hana e pili ana i nā hōʻike a me ka mālama maʻi. E ʻimi mākou i nā ʻanuʻu like ʻole o ccRCC a me nā lāʻau lapaʻau i hoʻohana ʻia i kēlā me kēia pae, e hōʻike ana i ke koʻikoʻi o ka ʻike mua a me ka hoʻokele proactive. No ka hoʻonaʻauao kēia ʻike a ʻaʻole pono e manaʻo ʻia he ʻōlelo aʻoaʻo olakino. E kūkākūkā mau me kāu ʻoihana mālama ola no nā hoʻolālā lapaʻau pilikino.

ʻO ka hōʻoia a me ke kau ʻana o ka ccRCC

ʻO ka hōʻoia pololei a me ka hoʻonohonoho ʻana he mea nui i ka hoʻoholo ʻana i ka hoʻolālā lapaʻau kūpono loa no maʻemaʻe cell renal cell carcinoma. He mea koʻikoʻi nā ʻenehana kiʻi kiʻi, e like me CT scans a me MRI, no ka ʻike ʻana i ka nui o ka ʻōpū, kahi, a me ka laha ʻana. Hana pinepine ʻia nā biopsies no ka hōʻoia ʻana i ka maʻi maʻi a hoʻoholo i ke ʻano kikoʻī o ka maʻi maʻi ʻaʻai, me ka loaʻa ʻana o ccRCC. ʻO nā ʻōnaehana staging, e like me ka TNM staging system, hoʻokaʻawale i ka nui o ka maʻi kanesa, e hoʻohuli ana i nā hoʻoholo lapaʻau. ʻO ka ʻike mua ʻana, ma o ka nānā mau ʻana a me ka hoʻokolokolo wikiwiki ʻana i nā hōʻailona, ​​​​e hoʻomaikaʻi nui i ka prognosis.

Ka hoʻomaopopo ʻana i ka TNM Staging System

Hoʻohana ka ʻōnaehana staging TNM i ʻekolu mau mea e hoʻokaʻawale maʻemaʻe cell renal cell carcinoma: T: Hōʻike i ka nui a me ka nui o ka maʻi maʻi mua. N: Hōʻike i ke komo ʻana o nā pūnana lymph kokoke. M: Hōʻike inā ua metastasized (laha) ke kanesa i nā ʻōpū mamao. Loaʻa i kēlā me kēia o kēia mau mea kahi pae helu (e laʻa, T1, T2, etc.), e hāʻawi ana i kahi loiloi piha o ka holomua o ka maʻi. ʻO ka hui pū ʻana o nā pae T, N, a me M e hāʻawi i kahi pae holoʻokoʻa no ka maʻi kanesa.

Nā koho lapaʻau no ccRCC

Nā koho lapaʻau no maʻemaʻe cell renal cell carcinoma ʻokoʻa nui ma muli o ke kūlana o ka maʻi kanesa a me ke olakino holoʻokoʻa o ka mea maʻi. ʻO ka ʻoki ʻoki ʻana ka mea maʻamau ka mālama mua ʻana no ka ccRCC kūloko, ʻoiai ʻo nā lāʻau lapaʻau ʻōnaehana, e komo pū ana i ka lāʻau lapaʻau a me ka immunotherapy, hoʻohana mau ʻia no ka maʻi holomua a metastatic paha.

ʻOki ʻokiʻoki

No ka ʻāina maʻemaʻe cell renal cell carcinoma, ka wehe 'ana i ka ma'i koko a i 'ole kekahi hapa a i 'ole nā pu'upa'a i ho'opilikia 'ia (partal nephrectomy a radical nephrectomy) 'o ia ka lālani mua o ka lā'au lapa'au. ʻO ka koho ma waena o kēia mau kaʻina hana e pili ana i nā kumu he nui, e like me ka nui o ka maʻi, kahi, a me ke olakino holoʻokoʻa o ka mea maʻi. ʻOi aku ka makemake o nā ʻenehana hōʻemi liʻiliʻi, e like me ka ʻoki laparoscopic, e hōʻemi ana i ka manawa hoʻōla a me nā pilikia.

ʻO ka Lapaʻau Kūlohelohe

Hana ʻia nā lāʻau lapaʻau i hoʻopaʻa ʻia ma ke kāohi ʻana i nā molekole kikoʻī e kōkua i ka ulu ʻana o ka tumor. Ua hōʻike maikaʻi ʻia kekahi mau lāʻau lapaʻau i hoʻopaʻa ʻia maʻemaʻe cell renal cell carcinoma, ʻoi aku ka poʻe e kuhikuhi ana i ka mea hoʻonui endothelial vascular (VEGF) a me ka pahuhopu mammalian o rapamycin (mTOR). ʻO nā laʻana he sunitinib, sorafenib, pazopanib, a me everolimus. Hiki ke hāʻawi waha ʻia kēia mau lāʻau lapaʻau a hoʻohana pinepine ʻia e like me ka lāʻau lapaʻau mua a i ʻole laina lua no ka metastatic ccRCC. He mea maʻamau nā hopena ʻaoʻao a hiki ke ʻokoʻa i waena o nā kānaka. E nānā pono kāu oncologist iā ʻoe i ka wā mālama.

Immunotherapy

Hoʻohana ka Immunotherapy i ka ʻōnaehana pale ʻana o ke kino e hakakā i nā maʻi maʻi maʻi. ʻO nā mea hoʻopaʻapaʻa ʻo Checkpoints, e like me ka nivolumab a me ka ipilimumab, hoʻopaʻa i nā wahi hoʻopaʻa palekana, e ʻae ana i ka ʻōnaehana pale e ʻike a hoʻouka i nā maʻi maʻi maʻi ʻoi aku ka maikaʻi. Hoʻohana pinepine ʻia kēia mau lāʻau lapaʻau i ka holomua a i ʻole ka metastatic maʻemaʻe cell renal cell carcinoma a hiki ke hui pū ʻia me ka lāʻau lapaʻau i hoʻopaʻa ʻia no nā hopena maikaʻi. Hiki i ka Immunotherapy ke hoʻopuka i nā hopena koʻikoʻi, me nā pilikia autoimmune, e koi ana i ka mālama olakino pili.

Lapaʻau Radiation

ʻOiai ʻaʻole maʻamau ka lāʻau lapaʻau mua no ka ccRCC, hiki i ka radiation therapy ke pāʻani i ke kuleana kākoʻo i ka mālama ʻana i ka ʻeha mai nā metastases iwi a i ʻole ka mālama ʻana i ka hoʻi hou ʻana o ka wahi ma hope o ke kaʻina.

Nā hoʻokolohua lapaʻau

ʻO nā maʻi me maʻemaʻe cell renal cell carcinoma pono e noʻonoʻo e komo i nā hoʻokolohua lapaʻau. Hāʻawi nā hoʻokolohua lapaʻau i ke komo ʻana i nā lāʻau lapaʻau hou a kōkua i ka holomua o ka noiʻi maʻi kanesa. Hiki i kāu kauka ke kōkua iā ʻoe i ka loaʻa ʻana o nā manawa hoʻokolohua lapaʻau kūpono. ʻO Shandong Baofa Cancer Research Institute https://www.baofahospital.com/ ua hoʻolaʻa ʻia i ka hoʻolako ʻana i ka mālama maʻi maʻi holomua a alakaʻi i ka noiʻi e kālele ana i ka hoʻomaikaʻi ʻana i nā hopena no nā maʻi.

Ka nānā ʻana a me ka hahai ʻana

Ma hope o ka hoʻomaʻamaʻa ʻana, he mea koʻikoʻi nā koho maʻamau no ka nānā ʻana no ka hoʻi hou ʻana a i ʻole ka ulu ʻana o nā maʻi maʻi hou. Hoʻohana pinepine ʻia nā haʻawina kiʻi a me nā hoʻāʻo koko e nānā i ka piʻi ʻana o ka maʻi. ʻO ka ʻike mua ʻana o ka hoʻi hou ʻana e hiki ai ke hana koke a hiki ke hoʻomaikaʻi i nā hopena.

ʻAno Lapaʻau	Mechanism	Ka pae o ccRCC	Nā hopena ʻaoʻao maʻamau
ʻOki ʻokiʻoki	Ka wehe kino o ke koko	ccRCC kūloko	ʻEha, maʻi, kahe koko
ʻO ka Lapaʻau Kūlohelohe	Ka hoʻopaʻa ʻana i nā molekole kikoʻī	Metastatic ccRCC	Ka luhi, nausea, hypertension
Immunotherapy	ʻO ka hoʻoulu ʻana i ka ʻōnaehana pale	Metastatic ccRCC	ʻO ka luhi, ka ʻili ʻili, nā pilikia autoimmune

Hōʻole: No ka hoʻonaʻauao wale nō kēia ʻike a ʻaʻole pono e manaʻo ʻia he ʻōlelo aʻoaʻo olakino. E kūkākūkā mau me kekahi ʻoihana mālama ola kūpono no ka hōʻoia ʻana a me ka mālama ʻana i kekahi maʻi olakino.